The acquisition positions Valeant to capitalize on growing eye-health trends driven by an aging patient population, an increased rate of diabetes and dand from erging markets. The combined business will also benefit from access to a strong product portfolio and a late-stage pipeline of innovative, new products.Valeant completed the acquisition of Bausch + Lomb Holdings Incorporated on 5 August.Mr Dan Spira, Valeant’s current managing director for Australia and New Zealand (including iNova Pharmaceuticals) will continue as managing director for the region.Bausch + Lomb’s former managing director in Australia and New Zealand, Mr Fabian Dwyer, has left the company.
Daylight saving linked to retinal disease risk, US study finds
The switch to daylight saving may increase the risk of developing serious retinal disease, according to a large US study....
